Titlebook: Urologic Oncology; Multidisciplinary Ca Kelly L. Stratton,Alicia K. Morgans Book 2022 The Editor(s) (if applicable) and The Author(s), unde

細(xì)節(jié)

Treatment of Metastatic Hormone-Sensitive Prostate Cancer,cetaxel, abiraterone acetate, enzalutamide, and apalutamide – have data demonstrating improved survival when used in addition to standard androgen deprivation therapy (ADT). No direct comparisons between these agents have been performed, and questions remain regarding optimal sequencing, although ov

有權(quán)威

Flirtatious

Costume

Radiotherapy for Advanced Prostate Cancer,he role of local therapy in patients with metastatic malignancies. As demonstrated in breast cancer, the benefit of local therapy is more pronounced in presence of effective systemic therapies [5]. Similar advancements have been noticed in prostate cancer. From the approval of docetaxel in the early

beta-carotene

小爭吵

高興一回

Jingoism

魅力

Treatment of Metastatic Bladder Cancer,inct therapeutic classes to further improve outcomes for patients with metastatic bladder cancer. This chapter focuses on the current therapeutic options for metastatic bladder cancer and gives a perspective on the future treatment of this disease.

chronology

Book 2022ensitive metastatic prostate cancer, neoadjuvant chemotherapy for muscle invasive bladdercancer, and immunotherapy approaches to advanced bladder and kidney cancer. The book also discusses the integration of genomic tumor characterization and personalized medicine into surgical planning, tumor biops